Induct AS (OSL:INDCT)
0.6380
0.00 (0.00%)
At close: Sep 14, 2026
Induct AS Revenue
Induct AS had revenue of 3.45M NOK in the quarter ending June 30, 2026, a decrease of -29.55%. This brings the company's revenue in the last twelve months to 13.72M, down -32.45% year-over-year. In the year 2025, Induct AS had annual revenue of 16.71M, down -15.47%.
Revenue (ttm)
13.72M
Revenue Growth
-32.45%
P/S Ratio
1.65
Revenue / Employee
932.72K
Employees
13
Market Cap
19.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.71M | -3.06M | -15.47% |
| Dec 31, 2024 | 19.77M | -3.68M | -15.70% |
| Dec 31, 2023 | 23.45M | 4.02M | 20.68% |
| Dec 31, 2022 | 19.44M | -10.86M | -35.84% |
| Dec 31, 2021 | 30.29M | 7.09M | 30.56% |
| Dec 31, 2020 | 23.20M | 9.42M | 68.32% |
| Dec 31, 2019 | 13.79M | -1.01M | -6.83% |
| Dec 31, 2018 | 14.80M | 1.35M | 10.07% |
| Dec 31, 2017 | 13.44M | 6.63M | 97.41% |
| Dec 31, 2016 | 6.81M | 2.15M | 46.27% |
| Dec 31, 2015 | 4.66M | -18.22M | -79.65% |
| Dec 31, 2014 | 22.87M | 3.11M | 15.75% |
| Dec 31, 2013 | 19.76M | 9.00M | 83.71% |
| Dec 31, 2012 | 10.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medistim ASA | 752.84M |
| Nordhealth AS | 601.42M |
| Arctic Bioscience AS | 48.96M |
| CodeLab Capital AS | 32.25M |
| Observe Medical ASA | 21.91M |
| SoftOx Solutions AS | 16.27M |
| Lifecare ASA | 7.67M |
| Aqua Bio Technology ASA | 5.67M |
Induct AS News
- 4 weeks ago - Induct AS Quarterly report: Q2 2026 - Filings
- 2 months ago - Induct AS Slides: Company presentation - Filings
- 4 months ago - Induct AS Quarterly report: Q1 2026 - Filings
- 7 months ago - Induct AS Quarterly report: Q4 2025 - Filings
- 7 months ago - Induct AS Annual report: Q4 2025 - Filings
- 10 months ago - Induct AS Quarterly report: Q3 2025 - Filings